PNC-27 is a synthetic peptide that fuses a p53–derived HDM-2–binding domain to a membrane-penetrating “leader” sequence. In published laboratory studies, it has been investigated for selectively inducing membrane disruption (necrosis) in cancer cells that express HDM-2 at their plasma membrane, while reportedly sparing normal cells in those same in-vitro models. PNC-27 is an experimental research compound. The information below summarizes preclinical, in-vitro and cell-line findings only. It is provided strictly for research and educational reference. PNC-27 is not a drug, not a treatment, and is not approved for human or veterinary use.
Research-use-only (RUO) note: nothing here describes a therapy, a clinical benefit, or any outcome in humans. All effects discussed were observed in cultured cells or laboratory models.
Quick facts
- Class: p53/HDM-2 membrane-disrupting (membranolytic) research peptide.
- Design: a chimeric peptide — a p53-derived HDM-2–binding segment joined to a membrane-residency / cell-penetrating “leader” sequence.
- Research focus: in-vitro investigation of cancer-cell-selective membrane disruption tied to HDM-2 localized at the cell membrane.
- Status: experimental; studied in cultured cells and laboratory models only. Not approved; not a treatment.
- Bolt Peptide does not sell PNC-27. This article is educational only.
What is PNC-27?
PNC-27 is a laboratory-synthesized chimeric peptide. One portion is derived from the tumor-suppressor protein p53 — specifically the region of p53 that binds HDM-2 (the human homolog of MDM-2), the protein cells use to regulate p53. The other portion is a membrane-penetrating leader sequence that allows the peptide to associate with and cross cell membranes. Because it joins a targeting domain to a membrane-active domain, researchers classify PNC-27 as a membranolytic, or membrane-disrupting, peptide rather than a conventional signaling peptide. In the literature it is described as an “anti-cancer” research peptide — terminology that refers to its behavior in cultured cancer cells, and does not imply any tested or approved use in people.
What does the research show?
Across cell-line studies, PNC-27 has been reported to bind HDM-2 in a conformation closely resembling the natural p53–HDM-2 interaction, and to trigger formation of transmembrane pores that lead to cancer-cell lysis. In one structural study using cancer cell lines and untransformed fibroblasts, electron microscopy with immunogold labeling visualized pores lined with PNC-27–HDM-2 complexes, and the peptide selectively lysed cancer-cell membranes while leaving the normal-cell controls intact (Sarafraz-Yazdi et al., 2022). Earlier work reported that PNC-27 kills cultured cancer cells — but not normal cells — by targeting HDM-2 specifically where it is present in the cell membrane (Michl, Pincus et al., 2010). A later mechanistic study in human pancreatic carcinoma cells additionally reported that, after engaging membrane-bound hdm-2, PNC-27 entered cells and associated with mitochondrial membranes, contributing to mitochondrial disruption (Krzesaj et al., 2024). Every one of these findings comes from in-vitro / cell-culture experiments. None demonstrates safety or effectiveness in humans.
Mechanisms studied in the lab
- HDM-2 membrane binding: the p53-derived domain binds HDM-2 located at the plasma membrane of cancer cells, anchoring the peptide where HDM-2 is exposed.
- Pore formation / necrosis: bound peptide–HDM-2 complexes are reported to assemble transmembrane pores, compromising membrane integrity and producing necrotic (rather than apoptotic) cell death in culture.
- Reported cancer-cell selectivity: in the cited models, normal cells that do not display HDM-2 at the membrane were not lysed — consistent with a membrane-HDM-2–dependent mechanism.
Research status
PNC-27 is an experimental research compound. Its characterization rests on in-vitro and cell-line work; the selectivity and mechanisms described above have been observed in laboratory systems, not in clinical use. PNC-27 is not approved by the FDA or any regulatory body, is not a medicine, and is not a cancer treatment. It is appropriate only for qualified in-vitro research conducted under proper institutional and safety oversight. Bolt Peptide does not sell PNC-27.
Related research compounds
Researchers exploring p53/HDM-2 biology and membrane-active peptides often review the broader landscape of research peptides. Browse the available research-use-only research peptide catalog. (PNC-27 itself is not part of the catalog and is covered here for educational purposes only.)
FAQ
Is PNC-27 a cancer treatment? No. PNC-27 is an experimental research peptide studied only in cultured cells and laboratory models. It is not approved, not a drug, and not a treatment for cancer or any other condition in humans or animals.
What makes PNC-27 different from other peptides? It is a chimeric design: a p53-derived HDM-2–binding domain fused to a membrane-penetrating sequence. Rather than acting as a signaling molecule, it has been studied for physically disrupting the membranes of cancer cells that present HDM-2 at the cell surface.
Does Bolt Peptide sell PNC-27? No. Bolt Peptide does not offer PNC-27. This article is purely educational. For research-use-only compounds we do carry, see the peptides catalog.
References
- Sarafraz-Yazdi E, et al. PNC-27, a Chimeric p53-Penetratin Peptide, Binds HDM-2 and Induces Selective Membrane-Pore Formation and Cancer Cell Lysis. Biomedicines. 2022.
- Michl J, et al. (Pincus MR). Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding HDM-2 in their membranes. PNAS. 2010.
- Krzesaj P, et al. (Pincus MR). PNC-27 interactions with plasma membrane-bound hdm-2 and mitochondrial membranes. Ann Clin Lab Sci. 2024.
For research use only. PNC-27 is an experimental compound studied only in vitro; not a drug and not FDA-approved; not for human or veterinary use. Bolt Peptide does not sell it. Statements have not been evaluated by the FDA.
Shop peptides from Bolt Peptide
Review current product availability and available documentation before ordering. Reference-lot records do not confirm the lot that will ship.
Browse Peptides →
